Calibre Health Labs has secured CQC registration, allowing its doctors to provide clinical care directly to members as the company expands its AI-powered health service across the UK.

CQC registration enables nationwide expansion

The registration means Calibre can now hold the clinical relationship with its members directly, with registered doctors responsible for clinical decisions, including ordering and interpreting diagnostic tests and providing personalised medical advice and care.

Calibre launched from early access in London in April 2026, backed by a $3.3m pre-seed funding round led by Amino Collective. The company says its nationwide launch is designed to combine doctors, diagnostic testing and causal AI to provide continuous health monitoring and personalised care.

The company is targeting adults aged 30 to 50, initially focusing on daily energy and longer-term health risks. Its approach combines medical history, lifestyle information, wearable data and diagnostic testing to identify factors that may be contributing to an individual’s health.

CQC registration is a significant step for the company because regulated healthcare providers in England must register with the regulator before carrying out activities within its scope.

The company previously said its clinical care was being delivered through CQC-registered provider DocTap while its own registration application was being processed. Its current service now states that clinical care and interpretation are delivered directly by Calibre as a CQC-regulated provider.

Diagnostic partnerships expand access

Calibre’s nationwide rollout is supported by a partnership with diagnostics company Randox, giving members access to more than 40 clinics across the UK.

The company will also introduce at-home phlebotomy through Heim later this month, allowing members to have blood and urine samples collected at home or at their workplace.

Calibre says its health assessments use diagnostic testing alongside medical history, lifestyle tracking and wearable data rather than relying on a single set of biomarkers. Its current service includes a personalised blood and urine test covering more than 50 biomarkers, followed by a health assessment with a dedicated doctor.

The company said August was its strongest month of growth during the early-access period, with more than 40% of members selecting an annual plan. It also said more than a quarter of new members now come through referrals.

Calibre develops causal AI models

The company is also developing what it calls a “causal AI doctor” model, although the technology is currently intended to support rather than replace clinical decision-making.

Calibre builds causal models around individual health outcomes, using them to help doctors assess what may be driving a person’s health, which information to collect and which interventions could be considered.

The company says that, over time, these models could become capable of making clinical decisions autonomously if they meet the regulatory standards required for that use.

Alexander Weber, co-founder and CEO of Calibre, said: “Causal AI enables us to bring a comparable depth of care to millions – safely, and at a fraction of the cost.”

Calibre’s approach therefore currently combines human clinical oversight with AI-supported analysis, with the longer-term ambition of using increasingly autonomous systems for continuous personalised care.

The company said its aim is to use causal AI to make personalised healthcare available at greater scale, while doctors continue to oversee clinical care and decisions.

CQC guidance states that the use of AI in healthcare needs to comply with regulatory requirements and appropriate clinical governance, with the level of oversight depending on the potential risk to patients.

Calibre says the UK is its initial market, with plans for international expansion in the future.